Genetics of Marfan Syndrome: Practice Essentials, Pathophysiology, Epidemiology (original) (raw)

Practice Essentials

Marfan syndrome (MFS) is an inherited connective tissue disorder noteworthy for its worldwide distribution, relatively high prevalence, and clinical variability. This autosomal dominant syndrome has pleiotropic manifestations involving primarily the ocular, cardiovascular, and skeletal systems. [1, 2] Classic MFS (MFS type 1, MFS1) has been considered a condition caused by the deficiency of a structural extracellular matrix protein, fibrillin-1; however, studies of Marfan mouse models and Marfan-related conditions have expanded our current understanding to a pathogenic model that involves dysregulation of cytokine-transforming growth factor beta (TGF_β_) signaling. [3, 4] Patients who have clinical findings of MFS, as well as genetic variants in the transforming growth factor-beta receptor-1 gene (TGF β R1) or the transforming growth factor-beta receptor-2 gene (TGF β R2), are designated as having MFS type 2 (MFS2). [5]

Signs and symptoms of Marfan syndrome

Clinical presentations are as follows:

Workup in Marfan syndrome

Lab studies

Currently, the standard of care in MFS is to obtain confirmatory molecular diagnostics on patients with the syndrome and their family members, due to the variable expression of MFS and the diagnosable "look-alike" conditions.

Molecular studies of the fibrillin-1 (FBN1) gene should be performed in patients in whom MFS is suspected. Mutation analysis can identify the exact mutation in the fibrillin gene, and linkage analysis can be used to track an abnormal fibrillin gene within a family. [6]

Imaging studies

Chest radiography should be focused on apical blebs. Chest radiographs may also detect a thoracic aortic dissection by demonstrating enlargement of the aortic and cardiac silhouette. Pelvic radiography may be required if a positive finding of protrusio acetabula is needed for the diagnosis.

Standard echocardiography is valuable to assess mitral valve prolapse, left ventricular size and function, left atrial size, and tricuspid valve function.

Cross-sectional echocardiography is a common tool used to diagnose and manage aortic root dilatation. The upper limit of normal aortic root size is 1.9 cm/m2 of body surface area and is independent of the patient's sex.

Transesophageal echocardiography depicts the distal ascending and descending aorta and can provide assessment of prosthetic valves. Doppler echocardiography is useful to detect and grade the severity of aortic and mitral regurgitation.

Magnetic resonance imaging (MRI) is the best choice for assessing chronic dissection of any region of the aorta. Computed tomography (CT) scanning or MRI of the lumbosacral spine may be needed to detect dural ectasia.

Management of Marfan syndrome

General guidelines for all adults diagnosed with MFS are as follows [7, 8] :

Key issues in cardiovascular management are as follows [9] :

Cardiovascular surgery can substantially prolong survival. Prophylactic and emergency cardiovascular surgery is needed for treatment of aortic and mitral regurgitation, aortic aneurysm, and aortic dissection. Emergency surgical replacement of the aortic root is indicated for survivors of acute proximal aortic dissection.

Severe scoliosis requires surgery. Bracing has a limited role in treating the most severe form of infantile scoliosis. Surgery should not be performed on a child younger than 4 years, because many patients with large curves before this age spontaneously die of cardiac complications. Results of spinal fusion are better in children older than 5 years.

Other types of surgery include the following:

eMedicine Logo

Pathophysiology

Marfan syndrome (MFS) results from heterozygous mutations in the fibrillin-1 gene (FBN1; OMIM #134797), located on chromosome 15 at band q21.1 (15q21.1), which encodes for the glycoprotein fibrillin. Fibrillin is a major building block of microfibrils, which constitute the structural components of the suspensory ligament of the ocular lens and serve as substrates for elastin in the aorta and other connective tissues. Abnormalities involving microfibrils weaken the aortic wall. Progressive aortic dilatation and eventual aortic dissection occur due to the tension caused by left ventricular ejection impulses. Likewise, deficient fibrillin deposition leads to reduced structural integrity of the lens zonules, ligaments, lung airways, and spinal dura.

Production of abnormal fibrillin-1 monomers from the mutated gene disrupts the multimerization of fibrillin-1 and prevents microfibril formation. This pathogenetic mechanism has been termed dominant-negative because the abnormal fibrillin-1 disrupts microfibril formation (although other fibrillin genes still encode normal fibrillin). Evidence of this mechanism is shown in studies of cultured skin fibroblasts from patients with MFS who produce greatly diminished and abnormal microfibrils.

A study by Benarroch et al suggested that clinical variability in MFS may result from alternative splicing of FBN1. [10]

FBN1 mutations cause several Marfan-like disorders, such as the MASS (myopia, mitral valve prolapse, borderline and nonprogressive aortic enlargement, nonspecific skin and skeletal findings) phenotype and isolated ectopia lentis.

Studies have suggested that abnormalities in the transforming growth factor-beta (TGF_β_)-signaling pathway may represent a common pathway for the development of the Marfan phenotype. [11] This gene defect ultimately leads to decreased and disordered incorporation of fibrillin into the connective tissue matrix.

The identification of mutations in TGF β R2 in patients with MFS type 2 (MFS2 mapped at 3p24.2-p25) provided direct evidence of abnormal TGF_β_ signaling in the pathogenesis of MFS.

Abnormalities in TGF β R1 and TGF β R2 were also reported to cause a new dominant syndrome similar to MFS1; it was associated with aortic aneurysm and congenital anomalies, including Loeys-Dietz syndrome (LDS). LDS is an autosomal dominant aortic aneurysm syndrome with widespread systemic involvement (LDS; OMIM #609192). [11] These results define a new group of Marfan syndrome–related connective tissue disorders, namely, TGF_β_ signalopathies, and include LDS1 and LDS2 (TGFβR1 and TGFβR2) and the SMAD3 and TGFβ2 disorders, with the latter two being classified as Loeys-Dietz-like (or as LDS3 and LDS4).

Shprintzen-Goldberg syndrome (SGS) has been found to be caused by a pathogenic variant in the SKI gene, which encodes a negative regulator of TGF_β_ signaling. There is phenotypic overlap with MFS and LDS.

A variant of the fibrillin-2 gene, FBN2, causes congenital contractural arachnodactyly, known as Beals syndrome. [12]

eMedicine Logo

Epidemiology

Frequency

United States

MFS is one of the most common single-gene malformation syndromes. MFS1 affects about 1:5000 to 1:10,000 individuals. [13, 7] Estimates suggest that at least 200,000 people in the United States have MFS or a related connective-tissue disorder.

A study by Behr et al found that in patients presenting with a chief complaint of pectus deformity, the incidence of MFS was 5.3%, with the incidence being 20% in persons with combined type pectus deformity. [14]

International

No geographic predilection is known.

Mortality/Morbidity

Cardiovascular disease (aortic dilatation and dissection) is the major cause of morbidity and mortality in MFS. Without proper medical management, MFS can be lethal in young adulthood, with death occurring at an average age of 30-40 years.

Infant morbidity, as related to cardiovascular disease, is due to progression of mitral valve prolapse to mitral regurgitation and often occurs in conjunction with tricuspid prolapse and regurgitation. Progression to congestive heart failure is a leading cause of cardiovascular morbidity and mortality, as well as the leading indicator for cardiovascular surgery.

Death later in life is usually due to chronic aortic regurgitation and ascending aortic dissection. Dissection generally occurs at the aortic root and is uncommon in childhood and adolescence.

A Norwegian study, by Vanem et al, found that out of 84 adults with Marfan syndrome (MFS) first investigated in 2003-2004, 16 (19.0%) were deceased by 2014-2015 follow-up, including 11 (68.8%) who had died of cardiovascular causes. Standardized mortality ratios were 8.20 for men and 3.85 for women. [15]

A study by Reis et al of patients with Marfan syndrome (MFS) found that those who had an aortic root diameter of 45 mm or more at the time of diagnosis had a significantly worse survival rate over the study’s mean 12.4-year follow-up period. [16]

Race

Marfan syndrome is panethnic.

Sex

No sex predilection is known.

Age

MFS may be diagnosed prenatally, at birth, in childhood, during adolescence, or in adulthood. Neonatal presentation is associated with a severe clinical course.

Many clinical features are specific to age. Some features may not present until later in life, a situation that may make early diagnosis in childhood difficult.

eMedicine Logo

  1. Esfandiari H, Ansari S, Mohammad-Rabei H, Mets MB. Management Strategies of Ocular Abnormalities in Patients with Marfan Syndrome: Current Perspective. J Ophthalmic Vis Res. 2019 Jan-Mar. 14 (1):71-7. [QxMD MEDLINE Link]. [Full Text].
  2. Niwa K. Aortic dilatation in complex congenital heart disease. Cardiovasc Diagn Ther. 2018 Dec. 8 (6):725-38. [QxMD MEDLINE Link]. [Full Text].
  3. Benke K, Agg B, Szilveszter B, et al. The role of transforming growth factor-beta in Marfan syndrome. Cardiol J. 2013. 20 (3):227-34. [QxMD MEDLINE Link]. [Full Text].
  4. Bolar N, Van Laer L, Loeys BL. Marfan syndrome: from gene to therapy. Curr Opin Pediatr. 2012 Aug. 24(4):498-504. [QxMD MEDLINE Link].
  5. Salik I, Rawla P. Marfan Syndrome. StatPearls. 2023 Jan. [QxMD MEDLINE Link]. [Full Text].
  6. Renner S, Schuler H, Alawi M, et al. Next-generation sequencing of 32 genes associated with hereditary aortopathies and related disorders of connective tissue in a cohort of 199 patients. Genet Med. 2019 Jan 24. [QxMD MEDLINE Link].
  7. Dietz HC, Pagon RA, Adam MP, et al. Marfan Syndrome. GeneReviews. 1993. [QxMD MEDLINE Link]. [Full Text].
  8. von Kodolitsch Y, Robinson PN. Marfan syndrome: an update of genetics, medical and surgical management. Heart. 2007 Jun. 93(6):755-60. [QxMD MEDLINE Link].
  9. Dean JC. Marfan syndrome: clinical diagnosis and management. Eur J Hum Genet. 2007 May 9. [QxMD MEDLINE Link]. [Full Text].
  10. Benarroch L, Aubart M, Gross MS, et al. Reference Expression Profile of Three FBN1 Transcript Isoforms and Their Association with Clinical Variability in Marfan Syndrome. Genes (Basel). 2019 Feb 11. 10 (2):[QxMD MEDLINE Link]. [Full Text].
  11. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005 Mar. 37(3):275-81. [QxMD MEDLINE Link].
  12. Lee B, Godfrey M, Vitale E, et al. Linkage of Marfan syndrome and a phenotypically related disorder to two different fibrillin genes. Nature. 1991. 352:337-339.
  13. Pyeritz RE. The Marfan syndrome. Annu Rev Med. 2000. 51:481-510. [QxMD MEDLINE Link].
  14. Behr CA, Denning NL, Kallis MP, et al. The incidence of Marfan syndrome and cardiac anomalies in patients presenting with pectus deformities. J Pediatr Surg. 2018 Dec 27. [QxMD MEDLINE Link].
  15. Vanem TT, Geiran OR, Krohg-Sorensen K, Roe C, Paus B, Rand-Hendriksen S. Survival, causes of death, and cardiovascular events in patients with Marfan syndrome. Mol Genet Genomic Med. 2018 Nov. 6 (6):1114-23. [QxMD MEDLINE Link]. [Full Text].
  16. Reis JF, Mano TB, Rito T, et al. Long term follow-up of Marfan Syndrome - experience of an adult congenital heart disease centre. Am J Cardiovasc Dis. 2022. 12 (2):92-101. [QxMD MEDLINE Link]. [Full Text].
  17. Rose PS, Levy HP, Ahn NU, et al. A comparison of the Berlin and Ghent nosologies and the influence of dural ectasia in the diagnosis of Marfan syndrome. Genet Med. 2000 Oct. 2(5):278-82. [QxMD MEDLINE Link].
  18. Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010 Jul. 47(7):476-85. [QxMD MEDLINE Link].
  19. Faivre L, Collod-Beroud G, Ades L, et al. The new Ghent criteria for Marfan syndrome: what do they change?. Clin Genet. 2012 May. 81(5):433-42. [QxMD MEDLINE Link].
  20. Van de Velde S, Fillman R, Yandow S. Protrusio acetabuli in Marfan syndrome. History, diagnosis, and treatment. J Bone Joint Surg Am. 2006 Mar. 88(3):639-46. [QxMD MEDLINE Link].
  21. Jones KB, Sponseller PD, Erkula G, et al. Symposium on the musculoskeletal aspects of Marfan syndrome: meeting report and state of the science. J Orthop Res. 2007 Mar. 25(3):413-22. [QxMD MEDLINE Link].
  22. Avivi E, Arzi H, Paz L, Caspi I, Chechik A. Skeletal manifestations of Marfan syndrome. Isr Med Assoc J. 2008 Mar. 10(3):186-8. [QxMD MEDLINE Link]. [Full Text].
  23. Kjeldsen S, Andersen N, Groth K, et al. Ocular morbidity in Marfan syndrome: a nationwide epidemiological study. Br J Ophthalmol. 2022 Mar 22. [QxMD MEDLINE Link].
  24. Wozniak-Mielczarek L, Sabiniewicz R, Drezek-Nojowicz M, et al. Differences in Cardiovascular Manifestation of Marfan Syndrome Between Children and Adults. Pediatr Cardiol. 2019 Feb. 40 (2):393-403. [QxMD MEDLINE Link]. [Full Text].
  25. Altman A, Uliel L, Caspi L. Dural ectasia as presenting symptom of Marfan syndrome. Isr Med Assoc J. 2008 Mar. 10(3):194-5. [QxMD MEDLINE Link]. [Full Text].
  26. Lacassie HJ, Millar S, Leithe LG, et al. Dural ectasia: a likely cause of inadequate spinal anaesthesia in two parturients with Marfan's syndrome. Br J Anaesth. 2005 Apr. 94(4):500-4. [QxMD MEDLINE Link].
  27. Frydman M. The Marfan syndrome. Isr Med Assoc J. 2008 Mar. 10(3):175-8. [QxMD MEDLINE Link]. [Full Text].
  28. Tiecke F, Katzke S, Booms P, et al. Classic, atypically severe andneonatal Marfan syndrome: twelve mutations and genotype-phenotypecorrelations in FBN1 exons 24-40. Eur J Hum Genet. 2001. 9:13-21. [QxMD MEDLINE Link]. [Full Text].
  29. Agg B, Benke K, Szilveszter B, et al. Possible extracardiac predictors of aortic dissection in Marfan syndrome. BMC Cardiovasc Disord. 2014 Apr 11. 14:47. [QxMD MEDLINE Link]. [Full Text].
  30. de Vries BB, Pals G, Odink R, Hamel BC. Homozygosity for a FBN1 missense mutation: clinical and molecular evidence for recessive Marfan syndrome. Eur J Hum Genet. 2007 Sep. 15(9):930-5. [QxMD MEDLINE Link].
  31. Pyeritz RE. Evaluation of the adolescent or adult with some features of Marfan syndrome. Genet Med. 2012 Jan. 14(1):171-7. [QxMD MEDLINE Link].
  32. Nee J, Kilaru S, Kelley J, et al. Prevalence of Functional GI Diseases and Pelvic Floor Symptoms in Marfan Syndrome and Ehlers-Danlos Syndrome: A National Cohort Study. J Clin Gastroenterol. 2019 Jan 21. [QxMD MEDLINE Link].
  33. Callewaert B, Malfait F, Loeys B, De Paepe A. Ehlers-Danlos syndromes and Marfan syndrome. Best Pract Res Clin Rheumatol. 2008 Mar. 22(1):165-89. [QxMD MEDLINE Link].
  34. Zhu L, Vranckx R, Khau Van Kien P, et al. Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet. 2006 Mar. 38(3):343-9. [QxMD MEDLINE Link].
  35. Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-betareceptor. New Engl J Med. 2006. 355:788-798.
  36. Glesby MJ, Pyeritz RE. Association of mitral valve prolapse and systemic abnormalities of connective tissue. A phenotypic continuum. JAMA. 1989 Jul 28. 262(4):523-8. [QxMD MEDLINE Link].
  37. Montgomery RA, Geraghty MT, Bull E, Gelb BD, Johnson M, McIntosh I, et al. Multiple molecular mechanisms underlying subdiagnostic variants of Marfan syndrome. Am J Hum Genet. 1998 Dec. 63(6):1703-11. [QxMD MEDLINE Link].
  38. Lieberman ER, Gomperts ED, Shaw KN, Landing BH, Donnell GN. Homocystinuria: clinical and pathologic review, with emphasis on thrombotic features, including pulmonary artery thrombosis. Perspect Pediatr Pathol. 1993. 17:125-47. [QxMD MEDLINE Link].
  39. Sood S, Eldadah ZA, Krause WL, McIntosh I, Dietz HC. Mutation in fibrillin-1 and the Marfanoid-craniosynostosis (Shprintzen-Goldberg) syndrome. Nat Genet. 1996 Feb. 12(2):209-11. [QxMD MEDLINE Link].
  40. Raymond FL, Tarpey PS, Edkins S, et al. Mutations in ZDHHC9, which encodes a palmitoyltransferase of NRAS and HRAS, cause X-linked mental retardation associated with a Marfanoid habitus. Am J Hum Genet. 2007 May. 80(5):982-7. [QxMD MEDLINE Link].
  41. Schwartz CE, Tarpey PS, Lubs HA, et al. The original Lujan syndrome family has a novel missense mutation (p.N1007S) in the MED12 gene. J Med Genet. 2007 Jul. 44(7):472-7. [QxMD MEDLINE Link].
  42. Summers KM, West JA, Peterson MM, et al. Challenges in the diagnosis of Marfan syndrome. Med J Aust. 2006 Jun 19. 184(12):627-31. [QxMD MEDLINE Link].
  43. Weigang E, Ghanem N, Chang XC, et al. Evaluation of three different measurement methods for dural ectasia in Marfan syndrome. Clin Radiol. 2006 Nov. 61(11):971-8. [QxMD MEDLINE Link].
  44. Faivre L, Masurel-Paulet A, Collod-Béroud G, Callewaert BL, Child AH, Stheneur C, et al. Clinical and molecular study of 320 children with Marfan syndrome and related type I fibrillinopathies in a series of 1009 probands with pathogenic FBN1 mutations. Pediatrics. 2009 Jan. 123(1):391-8. [QxMD MEDLINE Link].
  45. Frobel AK, Hulpke-Wette M, Schmidt KG, Laer S. Beta-blockers for congestive heart failure in children. Cochrane Database Syst Rev. 2009 Jan 21. CD007037. [QxMD MEDLINE Link].
  46. Williams A, Davies S, Stuart AG, Wilson DG, Fraser AG. Medical treatment of Marfan syndrome: a time for change. Heart. 2008 Apr. 94(4):414-21. [QxMD MEDLINE Link].
  47. Pyeritz RE. Marfan syndrome: 30 years of research equals 30 years of additional life expectancy. Heart. 2009 Mar. 95(3):173-5. [QxMD MEDLINE Link].
  48. Yetman AT, Bornemeier RA, McCrindle BW. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol. 2005 May 1. 95(9):1125-7. [QxMD MEDLINE Link].
  49. Ahimastos AA, Aggarwal A, D'Orsa KM, et al. Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. JAMA. 2007 Oct 3. 298(13):1539-47. [QxMD MEDLINE Link].
  50. Chung AW, Yang HH, Radomski MW, van Breemen C. Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9. Circ Res. 2008 Apr 25. 102(8):e73-85. [QxMD MEDLINE Link]. [Full Text].
  51. Chung AW, Au Yeung K, Sandor GG, Judge DP, Dietz HC, van Breemen C. Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in the thoracic aortic aneurysm in Marfan syndrome. Circ Res. 2007 Aug 31. 101(5):512-22. [QxMD MEDLINE Link].
  52. Kharrazi FD, Rodgers WB, Coran DL, Kasser JR, Hall JE. Protrusio acetabuli and bilateral basicervical femoral neck fractures in a patient with Marfan syndrome. Am J Orthop. 1997 Oct. 26(10):689-91. [QxMD MEDLINE Link].
  53. [Guideline] Harris EJ, Vanore JV, Thomas JL, et al. Diagnosis and treatment of pediatric flatfoot. J Foot Ankle Surg. 2004 Nov-Dec. 43(6):341-73. [QxMD MEDLINE Link].
  54. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006 Apr 7. 312(5770):117-21. [QxMD MEDLINE Link]. [Full Text].
  55. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med. 2008 Jun 26. 358(26):2787-95. [QxMD MEDLINE Link]. [Full Text].
  56. Pees C, Laccone F, Hagl M, Debrauwer V, Moser E, Michel-Behnke I. Usefulness of losartan on the size of the ascending aorta in an unselected cohort of children, adolescents, and young adults with Marfan syndrome. Am J Cardiol. 2013 Nov 1. 112 (9):1477-83. [QxMD MEDLINE Link].
  57. Lacro RV, Dietz HC, Sleeper LA, et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med. 2014 Nov 27. 371 (22):2061-71. [QxMD MEDLINE Link]. [Full Text].
  58. Chen H. Genetic Diagnosis and Counseling. 2nd ed. New York, NY: Springer; 2012. Vol 2: 1309-26.
  59. Stout M. The Marfan syndrome: implications for athletes and their echocardiographic assessment. Echocardiography. 2009 Oct. 26(9):1075-81. [QxMD MEDLINE Link].
  60. Van Lam H, Groth M, Mir T, et al. Impact of chest wall deformity on cardiac function by CMR and feature-tracking strain analysis in paediatric patients with Marfan syndrome. Eur Radiol. 2020 Dec 23. [QxMD MEDLINE Link]. [Full Text].
  61. Milewicz DM, Dietz HC, Miller DC. Treatment of aortic disease in patients with Marfan syndrome. Circulation. 2005 Mar 22. 111 (11):e150-7. [QxMD MEDLINE Link]. [Full Text].

Author

Germaine L Defendi, MD, MS, FAAP Associate Clinical Professor, Department of Pediatrics, Olive View-UCLA Medical Center

Germaine L Defendi, MD, MS, FAAP is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Chief Editor

Maria Descartes, MD Medical Geneticist, Miami Cancer Institute, Baptist Health South Florida

Maria Descartes, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics and Genomics, American Medical Association, American Society of Human Genetics, International Skeletal Dysplasia Society, Society for Inherited Metabolic Disorders, Southeastern Regional Genetics Group

Disclosure: Nothing to disclose.

Additional Contributors

Harold Chen, MD, MS, FAAP, FACMG Professor, Department of Pediatrics, Louisiana State University Medical Center

Harold Chen, MD, MS, FAAP, FACMG is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics and Genomics, American Medical Association, American Society of Human Genetics

Disclosure: Nothing to disclose.